SCHEMBL23568463

SCHEMBL23568463

CNCC1CCN(CC(C)C)CC1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.44
PIK3CD O00329 2/20 0.38
CARM1 Q86X55 4/20 0.38
PRMT6 Q96LA8 4/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
KCNH2 Q12809 3/20 0.36
CACNA1I Q9P0X4 2/20 0.36
HRH3 Q9Y5N1 1/20 0.36
HTT P42858 1/20 0.34
PRMT1 Q99873 1/20 0.34
PRMT8 Q9NR22 1/20 0.34
CYP2D6 P10635 1/20 0.33
CXCR4 P61073 1/20 0.33
ROCK2 O75116 1/20 0.33
ROCK1 Q13464 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23842228 0.85 HRH3 (0.39) L3MBTL1PIK3CDCARM1PRMT6KDM4E
SCHEMBL25480006 0.85 HRH3 (0.39) L3MBTL1PIK3CDCARM1PRMT6KDM4E
SCHEMBL25923737 0.84 PIK3CD (0.38) PIK3CDCARM1PRMT6KDM4EALDH1A1
SCHEMBL16748041 0.82 L3MBTL1 (0.43) L3MBTL1CARM1PRMT6KCNH2CACNA1I
SCHEMBL22856529 0.82 KDM4E (0.39) PIK3CDCARM1PRMT6KDM4EALDH1A1
SCHEMBL23567930 0.81 CARM1 (0.42) PIK3CDCARM1PRMT6HRH3PRMT1
SCHEMBL23841859 0.81 KCNH2 (0.40) PIK3CDCARM1PRMT6KDM4EALDH1A1
SCHEMBL21107430 0.79 PIK3CD (0.43) PIK3CDKDM4EALDH1A1TDP1HRH3
SCHEMBL25691521 0.79 PIK3CD (0.43) PIK3CDKDM4EALDH1A1TDP1HRH3
SCHEMBL23560007 0.78 SIGMAR1 (0.44) PIK3CDCARM1PRMT6HRH3PRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 US disclosed
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-13 US disclosed
US-20230144292-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-11 US disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 US disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 US disclosed
WO-2021127190-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 L3MBTL1 4553/4885PIK3CD 653/4885CARM1 4156/4885
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 L3MBTL1 1394/4885PIK3CD 321/4885CARM1 824/4885
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 L3MBTL1 1394/4885PIK3CD 321/4885CARM1 824/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 L3MBTL1 1394/4885PIK3CD 321/4885CARM1 824/4885
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 L3MBTL1 1394/4885PIK3CD 321/4885CARM1 824/4885
US-20230144292-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 L3MBTL1 1394/4885PIK3CD 321/4885CARM1 824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.